The Australian Managed Entry Scheme: Are We Getting it Right?

PharmacoEconomics
Haitham W Tuffaha, Paul A Scuffham

Abstract

In 2010, the Australian Government introduced the managed entry scheme (MES) to improve patient access to subsidised drugs on the Pharmaceutical Benefits Scheme and enhance the quality of evidence provided to decision makers. The aim of this paper was to critically review the Australian MES experience. We performed a comprehensive review of publicly available Pharmaceutical Benefits Advisory Committee online documents from January 2010 to July 2017. Relevant information on each MES agreement was systematically extracted, including its rationale, the conditions that guided its implementation and its policy outcomes. We identified 11 drugs where an MES was considered. Most of the identified drugs (75%) were antineoplastic agents and the main uncertainty was the overall survival benefit. More than half of the MES proposals were made by sponsors and most of the schemes were considered after previous rejected/deferred submissions for reimbursement. An MES was not established in 8 of 11 drugs (73%) despite the high evidence uncertainty. Nevertheless, six of these eight drugs were listed after the sponsors reduced their prices. Three MESs were established and implemented by Deeds of Agreement. The three cases were concluded and the re...Continue Reading

References

Nov 1, 1996·Health Economics·K Claxton, J Posnett
Oct 17, 2007·International Journal of Technology Assessment in Health Care·John HuttonChristopher Henshall
Jan 12, 2010·International Journal of Technology Assessment in Health Care·Paul TruemanKristen E Downs
May 16, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Simon WalkerSteve Palmer
May 16, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Michael WonderSean D Sullivan
Mar 22, 2014·Journal of Medical Economics·Haitham W TuffahaPaul A Scuffham
Jun 25, 2014·Health Policy·Agnes Vitry, Elizabeth Roughead
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Richard EdlinChristopher McCabe
Aug 26, 2014·PharmacoEconomics·Janneke P C GruttersManuela A Joore
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Mar 31, 2015·Journal of Pharmaceutical Policy and Practice·Christine Y LuAnita K Wagner
Oct 21, 2015·Journal of Pharmaceutical Policy and Practice·Agnes VitryElizabeth Roughead
Oct 8, 2016·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Karl ClaxtonClaire Rothery
Feb 6, 2017·The Medical Journal of Australia·Haitham W TuffahaPaul A Scuffham
Jul 12, 2017·PharmacoEconomics·Josh J CarlsonLouis P Garrison

❮ Previous
Next ❯

Citations

Jul 2, 2019·Applied Health Economics and Health Policy·Haitham W TuffahaPaul A Scuffham
Aug 12, 2020·PharmacoEconomics Open·Haitham Tuffaha
May 28, 2019·International Journal of Technology Assessment in Health Care·Linda MundyBrendon Kearney
Aug 1, 2020·PharmacoEconomics·Carolina Zampirolli DiasAugusto Afonso Guerra-Junior
May 29, 2021·Applied Health Economics and Health Policy·Haitham TuffahaStephen Birch

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Michael WonderSean D Sullivan
JAMA : the Journal of the American Medical Association
D A HenryAnthony Harris
International Journal of Technology Assessment in Health Care
Maxine F RobinsonElizabeth Roughead
The Medical Journal of Australia
D A Henry, D J Birkett
© 2022 Meta ULC. All rights reserved